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Summary
Familial hypoparathyroidism (also termed autosomal domi-
nant hypocalcemia) is characterized by hypocalcemia, hyper-
phosphatemia, and relative hypercalciuria, particularly during
treatment with vitamin D and calcium to correct the hypocal-
cemia. Serum parathyroid hormone is inappropriately sup-
pressed. Over 30 activating missense mutations in the calci-
um-sensing receptor gene have been identified in familial hy-
poparathyroidism. Functional expression studies in vitro
show that such mutations typically increase the receptor’s
sensitivity to Ca2+resulting in suppression of parathyroid hor-
mone secretion and increased urinary calcium excretion at in-
appropriately low concentrations of serum Ca2+. Identification
of calcium-sensing receptor gene mutations in subjects who
present with hypocalcemia is important to avoid development
of nephrolithiasis during treatment. Activating calcium-sens-
ing receptor gene mutations are non-randomly distributed in
the receptor protein. Study of these naturally occurring acti-
vating mutations has provided important insights into the
structure and function of the receptor.
KEY WORDS: calcium-sensing receptor, activating mutations, familial hy -
poparathyroidism, autosomal dominant hypocalcemia.
The expression cloning of the bovine calcium-sensing receptor
(CaR) just over a decade ago led immediately to studies show-
ing that this novel G protein-coupled receptor (GPCR) is abun-
dantly expressed in parathyroid and kidney where it mediates
direct control by serum Ca2+of parathyroid hormone (PTH) se-
cretion and urinary calcium excretion, respectively (1, 2). In-
creases in serum Ca2+activate the CaR and inhibit PTH secre-
tion from the parathyroid while decreasing reabsorption of fil-
tered calcium in the renal cortical thick ascending limb of Hen-
le. The physiologic importance of the CaR in regulating extra-
cellular Ca2+ homeostasis was further emphasized by the dis-
covery of inactivating mutations in the CaR gene as the cause
of familial hypocalciuric hypercalcemia (FHH) and neonatal se-
vere hyperparathyroidism, and of activating mutations in the
gene as the cause of familial hypoparathyroidism (FH, also
termed autosomal dominant hypocalcemia) (3). The phenotypic
consequences of loss of CaR function in FHH, hypercalcemia
and hypocalciuria, and of gain of CaR function in FH, hypocal-
cemia and hypercalciuria, are exactly what would be predicted
based on the demonstrated function of the CaR in mediating
the effects of serum Ca2+in the parathyroid and kidney. In this
review, we will focus on FH, and highlight its main genetic, di-
agnostic, and therapeutic features. We will also discuss how
the study of mutations identified in subjects with FH informs our
understanding of the structure and function of the CaR.
Familial hypoparathyroidism: discovery of CaR mutations
Familial isolated hypoparathyroidism is a rare disorder which
may be inherited in autosomal dominant, recessive, and X-
linked forms (4). Mutations in the PTH gene have been identi-
fied in both autosomal dominant and recessive forms, and loss
of function mutations in the GCMB transcription factor gene
have been found in other kindreds with autosomal recessive in-
heritance (5). However, many cases of isolated hypoparathy-
roidism remained unexplained until Finegold and colleagues, in
a large family with autosomal dominantly inherited isolated hy-
poparathyroidism, identified linkage to chromosome 3q13, the
region harboring the CaR gene (6). Subsequently, Pollak et al
described the first missense mutation in the CaR gene in a
family with autosomal dominant hypoparathyroidism (7). The
activating nature of the missense mutation they identified, an
increase in sensitivity (“left-shift” in dose-response) of the mu-
tated receptor to activation by Ca2 + compared with the wild
type receptor, provided a mechanism for the dominantly inherit-
ed phenotype. An activating mutation of a single allele of the
CaR gene by conferring increased sensitivity to activation by
Ca2+led to suppression of PTH secretion at inappropriately low
serum Ca2 +, thus resulting in hypocalcemia. Further study of
kindreds with activating CaR mutations also showed a tenden-
cy to hypercalciuria presumptively due to inhibition of calcium
reabsorption in the kidney by inappropriately low serum Ca2 +
concentration (8). To date, over thirty different activating muta-
tions have been identified in the CaR gene in subjects with FH
(9). Several of these have been identified multiple times in ap-
parently unrelated kindreds and individuals. The activating mu-
tations are illustrated in a schematic diagram of the human
CaR in Figure 1.
Familial hypoparathyroidism: genetic, clinical and diag-
nostic features
While hypocalcemia and relative hypercalciuria are the hall-
marks of FH caused by activating CaR mutation, the age of on-
set and severity of symptoms vary widely between different
f milies and even within a family with the identical mutation. In
some subjects, presentation in the form of seizures may occur
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shortly after birth (see for example 10), while in others, symp-
toms of hypocalcemia do not appear until adulthood, or not at
all. In one of the largest studies to date, severity of symptoms
was independent of age or mutation type but correlated with
the degree of hypocalcemia (11). Subjects generally show hy-
perphosphatemia, and there may be a tendency to hypomag-
nesemia, consistent with a role for the CaR in regulation of ex-
tracellular Mg2 +homeostasis (12). Serum intact PTH may be
undetectable or within the normal range, but is inappropriately
low for the concomitant hypocalcemia. Urinary calcium excre-
tion is higher than with other causes of hypoparathyroidism,
and this becomes exacerbated with treatment such as vitamin
D and calcium supplements to correct hypocalcemia. This
leads to a risk of nephrolithiasis, nephrocalcinosis and renal
damage (see Fig. 2). For this reason, some have argued that
subjects with FH who are asymptomatic should not be treated.
For those in whom symptoms of hypocalcemia demand treat-
ment, vitamin D must be administered cautiously with careful
monitoring of urinary calcium excretion. Thiazide diuretics have
been advocated to allow reduction in dose of vitamin D for cor-
rection of hypocalcemia and simultaneous reduction in hyper-
calciuria (13). In all cases the aim of treatment is to keep
serum calcium concentration at the lower limit of normal, to
prevent hypocalcemia-related symptoms. Synthetic 1-34 PTH
has also been used to treat subjects with FH, and appeared to
be effective in correcting hypocalcemia without inducing hyper-
calciuria (14). In essence, PTH replacement therapy bypasses
the inappropriate inhibition of PTH secretion caused by the ac-
ivating CaR mutation, but this form of therapy currently re-
quires multiple injections.
W ile a clear family history and autosomal dominant pattern of
inheritance are often found in subjects with FH caused by CaR
ctivating mutation, the disease appears to occur sporadically
in some individuals (15). This may be due to d n vo germline
mutations (10, 15), but in at least one family, there was evi-
d nce of germline mosaicism for an activating mutation of the
CaR gene (16). In this family, both parents were asymptomatic
and biochemically normal, but there were two affected siblings
w th the same activating CaR mutation, and the mother was
found to be a mosaic for the same mutation. It is important to
distinguish germline mosaicism from a true de novo mutation,
because of the different risk of having affected offspring in sub-
sequent pregnancies. Because there may not always be a pos-
itive family history, some have argued for screening for CaR
m tations in all subjects with isolated hypoparathyroidism. In-
de d, activating CaR mutations were identified in eight of nine-
teen probands with isolated hypoparathyroidism in one study
(11). Specific diagnosis of activating CaR mutation is important
because of the danger of hypercalciuria and nephrolithiasis if
hypocalcemia is too vigorously corrected in FH. 
In general, no clear pattern of genotype-phenotype correlation
has emerged in terms of type or location of CaR mutation, but
some suggestive differences have emerged (9). Functional ex-
pression studies of various CaR mutations in vitro h a v e
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Figure 1 - The amino acid sequence of the human calcium-sensing re-
ceptor (single letter code): cysteines (black), N-linked glycosylation
sites, signal peptide, beginning and end of venus flytrap domain, loops
1-4 of lobe 1 of the venus flytrap domain, and activating mutations (ar-
rows) identified in subjects with familial hypoparathyroidism are high-
lighted.
Figure 2 - Concomitant changes of serum calcium, phosphate and
magnesium, and urinary calcium excretion of monozygotic twins in
whom K29E mutation of the calcium-sensing receptor was identified
du ing treatment with oral calcium and dihydrotachysterol (from 2n d
postnatal week till age 20 months) or 1,25-dihydroxyvitamin D (from
age 20 months onward). Appearance of nephrocalcinosis, and treat-
ment with thiazide diuretics are shown. The shaded areas indicate nor-
mal ranges. (reproduced from Hu et al., JBMR 2004; 19:578-586)
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demonstrated quantitative differences in the degree of activa-
tion in terms of effective concentration 50% (EC5 0) for Ca2 +.
Certain mutations such as L125P that have been shown to be
particularly “left-shifted” in EC50 for Ca2+were identified in sub-
jects with early onset and severely symptomatic hypocalcemia,
and the mutation was found to occur de novo. This suggests
that there may be selection against such powerfully activating
mutations, and that they are less likely to occur on a familial
basis. A further example is the A843E mutation which was also
identified as a de novo mutation in a severely symptomatic
neonate (11). This mutation is unique in showing a significant
degree of constitutive activation in the absence of extracellular
C a2 + in in vitro expression studies (17). Interestingly, there
have been several reports of a Bartter-like syndrome with salt-
wasting, hypokalemic metabolic alkalosis, and hyperaldos-
teronemia, in subjects with FH and activating CaR mutations
(18, 19). Since there is evidence that CaR activation can inhibit
a renal outer medullary potassium channel, mutations of which
result in type 2 Bartter’s syndrome, it has been suggested that
features of this syndrome may be found in subjects with FH
caused by CaR mutations that are particularly activated. Con-
sistent with this hypothesis, mutations identified in such sub-
jects were L125P, A843E, and C131W, all among the most
powerfully activating CaR mutations identified (18, 19). The
CaR is expressed, albeit at lower levels, in many cells besides
the parathyroid and kidney, including brain, pancreatic islet and
gastrointestinal tract, and a variety of possible physiologic func-
tions beyond maintenance of extracellular Ca2 + h o m e o s t a s i s
have been suggested (20). Nonetheless, subjects with
germline activating CaR mutations have not demonstrated clin-
ical features that might be due to inappropriate CaR activation
in organs other than parathyroid and kidney. Of course, it re-
mains possible that more subtle defects may exist and further
studies along these lines are warranted.
Structure and function of the CaR: implications of activat-
ing mutations identified in FH
The CaR is a member of family 3 of the GPCR superfamily (9).
Family 3 is characterized by a large extracellular amino-termi-
nus consisting of two domains, a bilobed venus flytrap (VFT)
domain and a cysteine-rich domain, a seven-transmembrane
domain (7TM) typical of all GPCR, and a large intracellular car-
boxy-terminus (see Fig. 1). Family 3 GPCR exist as dimers,
and the CaR is an intermolecular disulfide-linked homodimer in
which C129 and C131are the residues involved in intermolecular
disulfide formation (9). X-ray crystallographic studies of the
closely related family 3 member, the metabotropic glutamate
receptor type 1, have directly demonstrated the dimeric nature
of the VFT domain (21). Furthermore, they have shown that
agonist binding occurs in the cleft between lobes 1 and 2 of the
bilobed VFT, and that such binding leads to a conformational
change involving not only closure of the VFT but also a 70° ro-
tation of one monomer relative to the other. In a manner as yet
unclear, this agonist-induced rotation of the VFT dimer is trans-
mitted via the cysteine-rich domain to the 7TM domain, causing
a conformational change in the latter that leads to activation
and G protein coupling. 
The location and nature of the activating mutations identified in
subjects with FH provide insights into the mechanism of CaR
activation. First, the distribution of activating mutations is not
random. Figure 1 depicts 32 missense mutations and one in-
frame deletion. Only the latter occurs in the intracellular car-
boxy-terminus. This mutation appears to activate by enhancing
receptor expression at the cell surface (11). The missense mu-
tations cluster in three parts of the receptor: thirteen are found
in the 7TM, sixteen in the proximal portion of the VFT and three
n a region that links the cysteine-rich domain to the 7TM do-
main. The activating mutations in the VFT appear in a homolo-
gy model of the CaR VFT based on the crystal structure of the
metabotropic glutamate receptor type 1 to cluster at the dimer
interface (9). This is particularly notable for a cluster of muta-
tions in loop 2 which is the site of intermolecular disulfide link-
age of the VFT dimer. We have suggested that such VFT mu-
tations activate by facilitating the dimer rotation ordinarily en-
gendered by agonist binding (22). In the case of the three mu-
tations in the linker region, it is tempting to speculate that this
li ker ordinarily is constrained in an inhibitory conformation that
is relieved by agonist binding. Activating mutations such as
E604K then would mimic agonist binding by relieving this in-
hibitory constraint. Mutations in the 7TM domain presumptively
facilitate conformational changes ordinarily transmitted from
the VFT as a consequence of agonist binding. In this regard,
the A843E mutation discussed above as unique in causing a
degree of constitutive activation, may operate by itself to pro-
mo e the conformation that leads to G protein coupling and ac-
tivation. Studies of a form of the CaR harboring the A843E mu-
tation, but in which the entire extracellular domain is deleted,
show that it is still constitutively activated, consistent with this
hypothesis (17).
Cl arly, the identification of activating mutations in the CaR as
the cause of FH has had important implications for diagnosis
 treatment of this disorder and for our understanding of
CaR structure and function. As we learn still more about the
precise structure and mechanism of activation of the CaR, we
can expect more targeted and effective forms of therapy for
subjects with FH.
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